NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that the U.S. Patent and Trademark Office (USPTO) has published on its website that the Company’s patent application No. 10/117,709 will issue on May 1, 2007 as U.S. Patent No. 7,211,267 (the ‘267 Oracea(R) Patent). This patent covers the use of sub-antimicrobial doses of tetracyclines, including Oracea, for the treatment of acne and acne rosacea. The USPTO published a notice of allowance of the ‘267 Oracea Patent in November 2006. CollaGenex received FDA approval for Oracea in May 2006 and is currently marketing Oracea to the U.S. dermatology community.
